Related references
Note: Only part of the references are listed.Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells
Georg Stary et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
The antitumoral mode of action of imiquimod and other imidazoquinolines
Margarete Schoen et al.
CURRENT MEDICINAL CHEMISTRY (2007)
Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines
Keith K. B. Gorden et al.
JOURNAL OF IMMUNOLOGY (2006)
Cutting edge: Activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides
Keith K. B. Gorden et al.
JOURNAL OF IMMUNOLOGY (2006)
Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells
Ofer Levy et al.
BLOOD (2006)
New insights into the regulation of TLR signaling
Sinead M. Miggin et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
TLR8-mediated NF-κB and JNK activation are TAK1-independent and MEKK3-dependent
Jinzhong Qin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Successful treatment of vulval melanoma in situ with topical 5% imiquimod cream
AA Lonsdale-Eccles et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides
Marion Jurk et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists
Kevin S. Gorski et al.
INTERNATIONAL IMMUNOLOGY (2006)
Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): A randomized, double-blind, placebo-controlled trial
GK Patel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion
Michael P. Schoen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Imiquimod for actinic keratosis: Systematic review and meta-analysis
Gina Hadley et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Nuclear factor-κB in cancer development and progression
Michael Karin
NATURE (2006)
Toll-like receptor agonists infl uence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
Ulrike Wille-Reece et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: Relation to central nervous system antitumor immunity
RM Prins et al.
JOURNAL OF IMMUNOLOGY (2006)
TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements
T Nishiya et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients - Randomized, double-blind, placebo-controlled trial
VL Brown et al.
ARCHIVES OF DERMATOLOGY (2005)
Suppression of RNA recognition by Toll-like receptors:: The impact of nucleoside modification and the evolutionary origin of RNA
K Karikó et al.
IMMUNITY (2005)
The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine
N Craft et al.
JOURNAL OF IMMUNOLOGY (2005)
The evolution of vertebrate Toll-like receptors
JC Roach et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease
M Odashima et al.
GASTROENTEROLOGY (2005)
Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production
JF Gerster et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma:: results from a randomized vehicle-controlled phase III study in Europe
HJ Schulze et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream
CM Ray et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2005)
Treatment of lentigo Maligna (melanoma in situ) with the immune response modifier imiquimod
IH Wolf et al.
ARCHIVES OF DERMATOLOGY (2005)
Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis - Results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials
N Korman et al.
ARCHIVES OF DERMATOLOGY (2005)
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
AD Judge et al.
NATURE BIOTECHNOLOGY (2005)
Cutting edge: Priming of CTL by transcutaneous peptide immunization with imiquimod
G Rechtsteiner et al.
JOURNAL OF IMMUNOLOGY (2005)
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7
V Hornung et al.
NATURE MEDICINE (2005)
Treatment of cutaneous metastatic melanoma with imiquimod 5% cream and the pulsed-dye laser
NC Zeitouni et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Imiquimod in the treatment of extensive recurrent lentigo maligna
A Kamin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)
Synthetic TLR Agonists reveal functional differences between human TLR7 and TLR8
KB Gorden et al.
JOURNAL OF IMMUNOLOGY (2005)
Treatment of patch and plaque stage mycosis fungoides with imiuquimod 5% cream
MJ Deeths et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)
Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials
M Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies
J Geisse et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the toll-like receptors
T Nishiya et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery
LL Thomsen et al.
VACCINE (2004)
Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA
AK Zuber et al.
VACCINE (2004)
Recognition of single-stranded RNA viruses by Toll-like receptor 7
JM Lund et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro
A Ambach et al.
MOLECULAR IMMUNOLOGY (2004)
Treatment of Bowen's disease with imiquimod 5% cream in transplant recipients
BM Prinz et al.
TRANSPLANTATION (2004)
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
SS Diebold et al.
SCIENCE (2004)
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
F Heil et al.
SCIENCE (2004)
Imiquimod-induced interleukin-1α stimulation improves barrier homeostasis in aged murine epidermis
CO Barland et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Interventions for basal cell carcinoma of the skin: systematic review
F Bath-Hextall et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis
D Vidal et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod
F Palamara et al.
JOURNAL OF IMMUNOLOGY (2004)
Imiquimod treatment induces expression of opioid growth factor receptor:: A novel tumor antigen induced by interferon-α?
M Urosevic et al.
CLINICAL CANCER RESEARCH (2004)
Topical immunomodulation in dermatology: Potential of Toll-like receptor agonists
UR Hengge et al.
DERMATOLOGIC SURGERY (2004)
A pilot study of treatment of lentigo maligna with 5% imiquimod cream
CJ Fleming et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology
RM Szeimies et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod
MP Schön et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle
B Berman et al.
BRITISH JOURNAL OF DERMATOLOGY (2003)
Imiquimod in basal cell carcinoma: how does it work?
R Dummer et al.
BRITISH JOURNAL OF DERMATOLOGY (2003)
Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses
K Loré et al.
JOURNAL OF IMMUNOLOGY (2003)
Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo
M Urosevic et al.
ARCHIVES OF DERMATOLOGY (2003)
Role of Toll-like receptors in costimulating cytotoxic T cell responses
K Schwarz et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7
J Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Topical imiquimod in the treatment of metastatic melanoma to skin
IH Wolf et al.
ARCHIVES OF DERMATOLOGY (2003)
The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum
D Roseeuw
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2003)
The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin
B Giannotti et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2003)
Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping
TP Sullivan et al.
DERMATOLOGIC SURGERY (2003)
The toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily
F Heil et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults
DN Sauder et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Topically applied imiquimod inhibits vascular tumor growth in vivo
R Sidbury et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures
T Meyer et al.
BRITISH JOURNAL OF DERMATOLOGY (2003)
Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides
R Dummer et al.
DERMATOLOGY (2003)
Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion
W Sterry et al.
BRITISH JOURNAL OF DERMATOLOGY (2002)
A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses
E Stockfleth et al.
ARCHIVES OF DERMATOLOGY (2002)
Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors
B Frotscher et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2002)
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential
MA Stanley
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2002)
Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread
S Ugurel et al.
BRITISH JOURNAL OF DERMATOLOGY (2002)
Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod
KR Suchin et al.
ARCHIVES OF DERMATOLOGY (2002)
Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod
SJ Gibson et al.
CELLULAR IMMUNOLOGY (2002)
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848
M Jurk et al.
NATURE IMMUNOLOGY (2002)
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
H Hemmi et al.
NATURE IMMUNOLOGY (2002)
Immunomodulation as a treatment strategy for genital herpes: review of the evidence
RL Miller et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2002)
Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma
AB Bong et al.
DERMATOLOGY (2002)
Imiquimod and resiquimod as novel immunomodulators
DH Dockrell et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy
KJ Smith et al.
DERMATOLOGIC SURGERY (2001)
Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases
E Stockfleth et al.
BRITISH JOURNAL OF DERMATOLOGY (2001)
Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis
S Buates et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment
DI Bernstein et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
The immune response modifier resiquimod mimics CD40-induced B cell activation
GA Bishop et al.
CELLULAR IMMUNOLOGY (2001)
Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day
H Gollnick et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2001)
The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes
MA Tomai et al.
CELLULAR IMMUNOLOGY (2000)
The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells
RP Burns et al.
CLINICAL IMMUNOLOGY (2000)
Topical imiquimod treatment of a cutaneous melanoma metastasis
A Steinmann et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2000)
Imiquimod, a topical immune response modifier, induces migration of Langerhans cells
H Suzuki et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2000)
Share Paper
